Post-approval studies (Phase 4)Not Yet RecruitingNCT07490509
What this trial is testing
Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer
Who this might be right for
AbemaciclibAbemaciclib-related DiarrheaBreast Cancer
Poitiers University Hospital 235